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Abstract: Background: In patients with COVID-19, cardiovascular complications are common and
associated with poor prognosis. Among these, an association between atrial fibrillation (AF) and
COVID-19 has been described; however, the extent of this relationship is unclear. The aim of this
study is to investigate the epidemiology of AF in COVID-19 patients and its impact on all-cause
mortality. Methods: A systematic review and meta-analysis were performed and reported according
to PRISMA guidelines, and a protocol for this study was registered on PROSPERO (CRD42021227950).
PubMed and EMBASE were systematically searched for relevant studies. A random-effects model
was used to estimate pooled odds ratios (OR) and 95% confidence intervals (CI). Results: Overall,
31 studies were included in the analysis, with a total number of 187,716 COVID-19 patients. The
prevalence of AF was found to be as high as 8% of patients with COVID-19 (95% CI: 6.3–10.2%, 95%
prediction intervals (PI): 2.0–27.1%), with a high degree of heterogeneity between studies; a multiple
meta-regression model including geographical location, age, hypertension, and diabetes showed that
these factors accounted for more than a third of the heterogeneity. AF COVID-19 patients were less
likely to be female but more likely older, hypertensive, and with a critical status than those without
AF. Patients with AF showed a significant increase in the risk of all-cause mortality (OR: 3.97, 95%
CI: 2.76–5.71), with a high degree of heterogeneity. A sensitivity analysis focusing on new-onset AF
showed the consistency of these results. Conclusions: Among COVID-19 patients, AF is found in 8%
of patients. AF COVID-19 patients are older, more hypertensive, and more likely to have a critical
status. In COVID-19 patients, AF is associated with a 4-fold higher risk of death. Further studies are
needed to define the best treatment strategies to improve the prognosis of AF COVID-19 patients.
Keywords: atrial fibrillation; COVID-19; prognosis; outcomes
1. Introduction
From early 2020, COVID-19 has caused a high burden of morbidity and mortality
worldwide [1]. Cardiovascular diseases were indicated among the leading causes of clinical
deterioration and adverse outcomes in these patients [2], and the association between
COVID-19 and cardiac arrhythmia has been described [3].
Atrial fibrillation (AF) is among the most common cardiac arrhythmias, and its associ-
ation between infectious diseases and critical illness has already been reported [4,5], with
a significant burden on management and prognosis [6,7]. Several hypotheses have been
proposed to explain the relationship between AF and infection, including cytokine storm,
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inflammation, and oxidative stress [5,8]. All these phenomena are also commonly reported
in COVID-19 patients [9].
Notwithstanding this, only few studies have reported about the onset of AF during
COVID-19 [3,10], and the actual prevalence and the impact of AF on the prognosis of these
patients are still unclear. On the other hand, AF is already recognized as the most common
arrhythmia occurring during COVID-19 [3,11,12]. This emphasizes the potential for a tight
relationship between these two diseases, as well as the clinical relevance of this association.
Although previous systematic reviews and meta-analyses have investigated the relationship
between AF and COVID-19, these were based on a limited number of patients, were not
focused on the AF episodes occurring during COVID-19, or did not provide an extensive
study of heterogeneity between studies [13–15]. A more comprehensive evaluation of the
relationship between AF and COVID-19, also taking into account those factors that may
influence the prevalence of AF and its related outcomes, is highly warranted to inform
physicians involved in the frontline of this pandemic [16].
We aimed to perform a systematic review and meta-analysis of the prevalence of
AF, factors associated with its onset, and the impact on all-cause mortality in patients
with COVID-19.
2. Methods
This systematic review was performed according to the Meta-analysis Of Obser-
vational Studies in Epidemiology (MOOSE) guidelines and reported according to the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines. A protocol for this study was registered into the international prospective register of
systematic reviews (PROSPERO), N. CRD42021227950.
2.1. Search Strategy
A systematic literature search was performed on PubMed and EMBASE databases,
from inception to 10 March 2021. Relevant key terms were combined in the search strategy,
including ‘Sars-CoV-2′, ‘COVID-19′, and ‘atrial fibrillation’. The full search strategy is
reported in Supplementary Materials (Supplementary Table S1).
2.2. Studies Selection
All articles retrieved from the literature search were systematically screened indepen-
dently by two investigators (G.F.R. and B.C.) according to titles and abstracts. Each article
included after the first screening phase was then evaluated independently by two investi-
gators (G.F.R. and B.C.) according to full-text eligibility. Disagreements were resolved by
collegial discussion with a third author (M.P.).
2.3. Inclusion and Exclusion Criteria
The main inclusion criteria were: (i) all studies reporting the prevalence of AF in
hospitalized patients with COVID-19; (ii) all studies reporting outcomes (i.e., mortality)
according to AF status in patients with COVID-19. For the purpose of this study, AF was
defined as the occurrence of AF during COVID-19, as defined in the original studies, and
irrespective of the previous history of AF. When a study reported on AF and atrial flutter
together, we included all patients under the AF definition, unless a clear distinction was
possible based on published data. We excluded studies on highly selected cohorts (e.g., only
deceased patients) of patients with COVID-19, conference abstracts, comments, editorials,
case reports, systematic reviews, and meta-analyses. In the case of duplicated cohorts
(i.e., two or more studies based on the same cohort of patients), we selected the study with
(i) the highest number of patients included, (ii) the most complete set of information, or
(iii) the most recently published one.
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2.4. Data Extraction and Quality Assessment
Data from the studies included were independently extracted by two investigators
(G.F.R. and B.C.) with the use of a standardized electronic form. We extracted data on
sample size, numbers of patients with AF, proportion of females, and prevalence of several
comorbidities (including hypertension, diabetes mellitus, coronary artery disease (CAD),
chronic heart failure (CHF), and chronic kidney disease (CKD)). We also extracted data on
the proportion of “critical” patients; since studies heterogeneously reported characteristics
related to COVID-19 severity, we defined “critical” patients as follows: (i) patients were
admitted to the ICU, (ii) patients underwent mechanical ventilation, or (iii) patients were
defined as “critical” in the original studies. Additionally, we extracted data regarding
outcomes (in-hospital death or 30-day mortality) according to the AF status, when available.
All studies included were independently evaluated by two investigators (G.F.R. and
B.C.) to assess the risk of bias. According to the outcomes investigated, we evaluated the
risk of bias separately for each outcome of the study: for the prevalence of AF, we assessed
the risk of bias using a customized version of the Newcastle–Ottawa scale (NOS) for cross-
sectional studies, composed of five items across three domains (selection, comparability,
outcome), with a maximum of 5 points. Any study with a score ≤3 was categorized as
being at a high risk of bias. For studies exploring outcomes according to AF status, we
assessed the risk of bias using a customized version of the NOS for cohort studies [17],
composed of eight items across three domains (selection, comparability, outcome). Any
study with a score ≤6 was categorized as being at a high risk of bias.
2.5. Outcomes Definition
Prevalence of AF was defined as the proportion of patients that present AF at admis-
sion or during the clinical course of COVID-19, as defined in the original studies.
We also investigated the association of AF with several conditions or baseline char-
acteristics of the COVID-19 patients, including age, female sex, history of hypertension,
diabetes mellitus, coronary artery disease (CAD), and chronic heart failure (CHF), as well
as the critical disease status as previously defined.
All-cause mortality was defined as the occurrence of in-hospital death or 30-days
death in patients with COVID-19, according to AF status.
2.6. Statistical Analysis
The prevalence of AF reported in the original studies included were pooled with
a random intercept logistic regression model [18], and reported as pooled prevalence,
95% confidence intervals (CI), and 95% prediction intervals (PI). PI represents a predicted
range of the true effect in a potential future study, and provides useful information on the
variability of the effect in different clinical settings [19,20].
Dichotomous variables were pooled and compared using random-effects models, and
reported as odds ratios (OR) mean difference and 95% CI. For continuous variables, mean,
SD, and total number in each group were pooled and compared with the inverse variance
method; mean difference and 95% CI were reported accordingly.
The inconsistency index (I2) was calculated to measure heterogeneity. According to
pre-specified cut-offs, low heterogeneity was defined as an I2 of <25%, moderate hetero-
geneity when I2 fell between 25 and 75%, and high heterogeneity when I2 was >75%.
For prevalence of AF and all-cause mortality, a sensitivity analysis was performed
with a “leave-one-out” approach, in which all studies are removed iteratively one at a time
to evaluate their influence on the pooled estimate and heterogeneity. As an additional
sensitivity analysis, we also computed the prevalence of AF according to the inverse
variance method, with two types of transformation of the proportions (logit transformation
and Freeman–Tukey double arcsine transformation).
To investigate the potential sources of heterogeneity in the pooled prevalence of AF,
we performed several subgroup analyses, according to geographical location, study design
(retrospective vs. observational), and risk of bias. Moreover, we also performed univariable
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and multivariable meta-regression, according to study-level relevant baseline characteris-
tics, to identify potential study-level characteristics associated with the prevalence of AF,
or the risk of all-cause mortality in patients with AF vs. those without AF.
A sensitivity analysis, including only patients with new onset AF (i.e., patients who
presented with AF during COVID-19, with the exclusion of those with a previous history
of AF) was also performed for both the prevalence of AF and all-cause mortality. For this
analysis, we excluded from the calculation those patients with a known history of AF. Only
those studies for which these data were available (or derivable from the main cohort), and
clearly referred to new onset AF, were included in this analysis.
Publication bias was assessed for studies reporting all-cause mortality according to
AF status, with the use of funnel plots, which were visually inspected for asymmetricity.
Egger’s test was also performed. In case of detection of significant publication bias, we
performed further analysis according to the trim-and-fill approach [21], in which additional
studies which correct for the asymmetry in the funnel plot are imputed and combined with
those included in the meta-analysis to analyze the actual effect of potential publication bias.
All the statistical analyses were performed using R version 4.0.3 (R Core Team, R
Foundation for Statistical Computing, Vienna, Austria, 2020), with the use of ‘meta’ [22],
‘metafor’ [23], and ‘dmetar’ [24] packages.
3. Results
Of the 783 studies identified from the literature search (216 on Pubmed and 567 on
EMBASE), 31 studies were selected according to the inclusion and exclusion criteria and
included in the analysis [3,10–12,25–51] (Figure S1 in Supplementary Materials), with a
total of 187,716 COVID-19 patients. Baseline characteristics of the studies included are
reported in Table 1.
Thirteen studies were held in Europe [10,11,25,29,31,33,37,39,42–44,47,50], nine in
North America [3,28,30,32,41,45,46,49,51], four in Asia [26,34,35,48], and five in other geo-
graphical locations, including one multinational study [12,27,36,38,40]. Twenty-five stud-
ies were observational retrospective [3,10,12,26,28,30–32,34,35,37–51], four were based on
prospective observational analysis of single center cohorts [11,25,29,36], while two were
observational prospective multicenter studies [27,33].
Of the studies, 14 were included in the analysis for all-cause mortality according to
AF status (12 reported in-hospital death [3,10,12,25,29,30,37,40–43,45] and two described
30-day mortality [32,50]). Nine studies included patients with new onset AF [10,29,36,37,
40–42,45,51]. To improve the reliability of our estimates, after careful evaluation of the
definitions of AF used and of the data reported, for two studies [37,51], we decided to
compute only new onset AF in the main analysis about prevalence.
The evaluation of bias for the two outcomes investigated is reported in Supplementary
Materials (Tables S2 and S3, respectively). Among studies reporting the prevalence of AF,
13 studies were categorized as being at high risk of bias [11,32–34,36,37,39,42,44,46–48,51];
incomplete reporting of baseline characteristics was the most common concern. Among
the studies reporting all-cause mortality according to AF, two studies were at high risk of
bias [42,50].
3.1. Prevalence of AF in Patients with COVID-19
In the 31 studies included, 8.0% of patients with COVID-19 presented AF (95% CI:
6.3–10.2%, 95% PI: 2.0–27.1%), with high heterogeneity between studies (Figure 1). The
leave-one-out sensitivity analysis showed consistent results (Supplementary Figure S2);
similar estimates were also found in the sensitivity analysis according to the inverse-
variance method, using different methods for transformation of the proportions (Supple-
mentary Table S4).
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Abe 2020 [46] United States Retrospective Hospitalizedpatients ECG changes 142 9 58 50 73 50 NA 11 NA
Angeli 2020 [47] Italy Retrospective Hospitalizedpatients Baseline ECG 50 3 64 28 50 12 0 NA NA
Bhatla 2020 [3] United States Retrospective Hospitalizedpatients ECG changes 700 25 50 55 50 26 11 6
In-hospital
mortality




ECG changes 54 1 57.7 33 30 46 100 NA NA
Colon 2020 [49] United States Retrospective Hospitalizedpatients
ECG,
telemetry 115 12 57.2 54 70 39 60 5 NA
Coromilas 2021 [38] Multinational Retrospective Hospitalizedpatients Baseline ECG 4526 595 62.8 43 55 35 20 9 NA
D’Andrea 2020 [39] Italy Retrospective Hospitalizedpatients ECG 280 51 66.6 40 35 NA NA NA NA




patients ECG 517 54 68.1 44 50 18 9 9
In-hospital
mortality
Harrison 2020 [51] United States Retrospective Patients ≥ 50years ICD-10 codes 68,975 2455 65.2 52 46 24 NA NA NA
Kelesoglu 2020 [40] Turkey Retrospective Hospitalizedpatients
ECG,
telemetry 658 33 54 43 32 18 9 0
In-hospital
mortality
Lanza 2020 [25] Italy Prospective ED admission Baseline ECG 324 20 65.9 34 52 11 14 NA In-hospitalmortality




patients ECG 3011 142 67 * 37 45 23 28 NA NA
Maeda 2020 [28] United States Retrospective Hospitalizedpatients ECG 181 9 64.0 44 65 34 18 13 NA
Mountantonakis












codes 3970 375 66 * 42 34 25 16 8
In-hospital
mortality
























Holter 160 12 65.7 40 47 16 4 19
In-hospital
mortality
Peltzer 2020 [30] United States Retrospective Hospitalizedpatients
ECG,
telemetry 1053 166 62.4 62 54 30 33 9
In-hospital
mortality
Piroth 2020 [31] France Retrospective Hospitalizedpatients ICD-10 codes 89,530 11,129 65 47 33 19 16 NA NA
Poterucha 2020 [32] United States Retrospective Hospitalizedpatients Baseline ECG 887 46 64.1 42 61 39 NA NA
30-days
mortality
Rav-Acha 2020 [12] Israel Retrospective Hospitalizedpatients ECG changes 390 20 57.5 * 45 30 20 10 7
In-hospital
mortality
Russo 2020 [10] Italy Retrospective ED admission Baseline ECG 414 71 66 38 64 26 NA 17 In-hospitalmortality
Sala 2020 [11] Italy Prospective Hospitalizedpatients Baseline ECG 132 8 65 33 45 20 0 12 NA
Santoro 2020 [33] Italy/Germany Prospective Hospitalizedpatients Baseline ECG 110 6 58 33 39 13 6 NA NA
Spinoni 2021 [42] Italy Retrospective Hospitalizedpatients ECG 637 134 NA NA NA NA NA NA
In-hospital
mortality
Vee 2020 [34] Malaysia Retrospective Hospitalizedpatients NA 247 2 28 * 30 11 7 2 NA NA
Wang 2020 [35] China Retrospective Hospitalizedpatients Baseline ECG 319 20 65 52 44 23 30 NA NA





notes 155 52 66 * 27 44 21 100 NA NA




ECG changes 140 13 51.7 51 47 34 NA 0 NA
Zylla 2021 [37] Germany Retrospective Hospitalizedpatients ECG changes 139 11 61.1 34 43 19 39 0
In-hospital
mortality
Legend: * median values; AF = atrial fibrillation; CKD = chronic kidney disease; CRIT = critical; DM = diabetes mellitus; ECG = electrocardiogram; ED = emergency department; F = females; HTN = hypertension;
ICD = International Classification of Diseases; NA = not available.
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Table 2. Univariable and multiple meta-regression * analysis for AF prevalence. 
Variable Coefficient Standard Error Lower 95% CI Upper 95% CI P R2 
Univariable Analysis       
Age 0.054 0.016 0.021 0.087 0.003 0.289 
Female sex 0.101 1.854 −3.710 3.911 0.957 0.000 
Hypertension 2.058 0.881 0.247 3.869 0.028 0.143 
Diabetes 1.826 1.130 −0.501 4.153 0.119 0.117 
Geographical location     0.067 0.191 
Europe (ref.)       
North America −0.331 0.277 −0.900 0.238 0.242  
Asia/other −0.702 0.287 −1.291 −0.113 0.021  
Multiple Analysis     0.019 
0.460 
Age 0.041 0.018 0.002 0.079 0.038 
Hypertension 0.115 1.357 −2.692 2.922 0.933 
Diabetes 3.081 1.855 −0.756 6.917 0.110 
Geographical location      
Europe (ref.)      
North America −0.676 0.344 −1.387 0.036 0.062 
Asia/other −0.589 0.348 −1.308 0.131 0.104 
Legend: * Maximum likelihood; for other acronyms, please see previous tables legends. 
Figure 1. Pooled prevalence of AF in COVID-19 patients. Legend: CI = confidence interval; GLMM = general linear
mixed model.
Pre-specified subgroup analyses are reported in Supplementary Table S5. Significant
differences were observed according to the geographical location of the included studies,
with the European-based cohorts showing a higher prevalence of AF (11.3%) compared to
other studies performed in North America or Asia/other geographical locations (7.5% and
5.3%, respectively). No significant differences were observed according to the study design
or the risk of bias.
The results of the meta-regressions are reported in Table 2. At univariable analysis,
only age and hypertension resulted significantly and directly associated to the prevalence
of AF; a similar, non-significant trend was also observed for geographical location and
diabetes (Table 2). A multivariable meta-regression model comprising geographical loca-
tion, mean age, history of hypertension, and history of diabetes was able to explain part
of the heterogeneity observed (R2 = 46.0%, p = 0.019). A graphical representation of the
relationship between the mean age of studies included and the prevalence of AF is reported
in Figure 2.
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Table 2. Univariable and multiple meta-regression * analysis for AF prevalence.
Variable Coefficient Standard Error Lower 95% CI Upper 95% CI p R2
Univariable Analysis
Age 0.054 0.016 0.021 0.087 0.003 0.289
Female sex 0.101 1.854 −3.710 3.911 0.957 0.000
Hypertension 2.058 0.881 0.247 3.869 0.028 0.143
Diabetes 1.826 1.130 −0.501 4.153 0.119 0.117
Geographical location 0.067 0.191
Europe (ref.)
North America −0.331 0.277 −0.900 0.238 0.242
Asia/other −0.702 0.287 −1.291 −0.113 0.021
Multiple Analysis 0.019
0.460
Age 0.041 0.018 0.002 0.079 0.038
Hypertension 0.115 1.357 −2.692 2.922 0.933
Diabetes 3.081 1.855 −0.756 6.917 0.110
Geographical location
Europe (ref.)
North America −0.676 0.344 −1.387 0.036 0.062
Asia/other −0.589 0.348 −1.308 0.131 0.104
Legend: * Maximum likelihood; for other acronyms, please see previous tables legends.
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senting with and without AF. Eight studies reported data disaggregated by AF diagnosis 
on proportion of female sex, hypertension, and diabetes [10,29,30,37,40,41,43,45]; seven 
reported about mean age [10,29,30,37,40,43,45] and CHF [10,29,30,40,41,43,45], while six 
reported on CAD [10,29,30,41,43,45]; finally, 12 reported on proportion of critical patients 
[3,26,29,30,35,37,40,41,45,48,49] (specifically, six according to ICU admission 
[3,26,29,30,43,49], two according to “critically ill” definition [35,48], one according to 
ICU/intermediate care unit admission [37], and two according to patients receiving me-
chanical ventilation [41,45]). 
Results for this analysis are reported in Table 3. AF was associated with older age 
(mean difference: 13.2 years, 95% CI 10.5–15.9) and a 17% lower likelihood of being fe-
male. AF patients were more likely affected by hypertension, diabetes mellitus, CAD, or 
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3.2. Clinical Characteristics of AF Patients with COVID-19
We compared several baseline characteristics and conditions between patients pre-
senting with and without AF. Eight studies reported data disaggregated by AF diagnosis
on proportion of female sex, hypertension, and diabetes [10,29,30,37,40,41,43,45]; seven
reported about mean age [10,29,30,37,40,43,45] and CHF [10,29,30,40,41,43,45], while six
reported on CAD [10,29,30,41,43,45]; finally, 12 reported on proportion of critical patients
[3,26,29,30,35,37,40,41,45,48,49] (specifically, six according to ICU admission [3,26,29,30,43,49],
two according to “critically ill” definition [35,48], one according to ICU/intermediate care
unit admission [37], and two according to patients receiving mechanical ventilation [41,45]).
Results for this analysis are reported in Table 3. AF was associated with older age
(mean difference: 13.2 years, 95% CI 10.5–15.9) and a 17% lower likelihood of being female.
AF patients were more likely affected by hypertension, diabetes mellitus, CAD, or CHF;
finally, they had a 3.6-fold higher chance of having a critical COVID-19 clinical course. Low
to moderate heterogeneity was found for all analyses, except for mean age, which showed
high heterogeneity (I2 = 86%).
Table 3. Association of clinical characteristics with AF.
Variable N◦ Studies MD 95% CI I2
Continuous Variables
Age 7 13.2 10.5–15.9 86%
Variable N◦ Studies OR 95% CI I2
Categorical Variables
Female sex 8 0.83 0.76–0.90 7%
Hypertension 8 2.49 2.25–2.75 0%
Diabetes 8 1.38 1.24–1.54 0%
CHF 7 4.45 3.21–6.18 58%
CAD 6 2.57 2.05–3.21 58%
Critical status 12 3.62 2.39–5.48 69%
Legend: AF = atrial fibrillation; CAD = coronary artery disease; CHF = congestive heart failure; CI = confidence
interval; MD = mean difference; OR = odds ratio.
3.3. All-Cause Mortality according to AF Status
In the 14 studies reporting on all-cause mortality among COVID-19 patients and
according to AF status, patients with AF showed a 4-fold higher risk of death compared to
patients without AF (OR: 3.97, 95%CI: 2.76–5.71, Figure 3), with high heterogeneity found
between studies (I2 = 78%). The leave-one-out analysis showed little to no effect of single
studies on the results (Figure S3).
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Figure 3. Risk of all-cause mortality in AF vs. non-AF patients. Legend: AF = atrial fibrillation; CI = confidence interval;
MH = Mantel–Haenszel.
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Subgroup analyses according to the outcome definition are reported in Figure S4.
Twelve studies reported in-hospital death [3,10,12,25,29,30,37,40–43,45] and two reported
30-days mortality [32,50]. Patients with AF showed both higher risk of in-hospital mortality
(OR 3.52, 95% CI 2.44–5.10) and 30-days mortality (OR 7.34, 95% CI: 3.11–17.34), with no
statistically significant difference between subgroups (p = 0.12; Figure S4).
Finally, we performed univariable and multivariable meta-regression analyses for all-
cause mortality. None of the predictors examined were found to be significantly associated
with risk of all-cause death (Table S6).
Significant publication bias was found across the 13 studies included in the analysis
(Egger’s test p = 0.002, Figure S5). Visual inspection of the funnel plot revealed a void
in the lower-left part of the diagram. The correction of the asymmetry of the funnel plot
according to the trim-and-fill approach did not affect the significance of the results, despite
lowering the pooled estimate (OR: 2.49, 95% CI: 1.58–3.92), suggesting that publication bias
is unlikely to contribute to the overall significance of our results.
3.4. Sensitivity Analysis about New-Onset AF
In this pre-specified sensitivity analysis about COVID-19 patients with a new-onset AF
(thus with the exclusion of those with a diagnosis of AF before occurrence of COVID-19),
nine studies were included for the prevalence of AF [10,29,36,37,40,41,45,51] and five for
all-cause mortality according to the AF status [10,37,40,42,45]. The prevalence of new-onset
AF was found as high as 7.4% (95% CI: 5.3–10.2%, Figure S6 Panel A in Supplementary
Materials), with a high grade of heterogeneity found between studies. New-onset AF
was also associated with a significant 2.4-fold higher risk of all-cause mortality compared
to patients with no AF (Figure S6, Panel B), with a low degree of heterogeneity found
between studies.
4. Discussion
In this systematic review and meta-analysis of 187,716 adults, AF was found in 8%
of COVID-19 patients; high heterogeneity was found between studies, and the 95% PI
indicated that actual prevalence of AF maybe up to 27%. AF COVID-19 patients were
more likely to be older, hypertensive, diabetic, with concomitant CAD and CHF, and in a
critical clinical status. Third, the presence of AF in COVID-19 patients was associated with
a 4-fold higher risk of death. Overall, there was consistency in all the sensitivity analyses
performed, even if confined to patients with new-onset AF.
Previous meta-analyses tried to investigate the relationship between AF and COVID-
19. However, these were based on significantly fewer studies and patients, and provided no
information on the potential reasons of the heterogeneity found [13,15]; similarly, another
systematic review that focused on outcomes [14] was not specifically designed to assess
the prognostic role of AF developing during COVID-19, since it also included those studies
that reported outcomes according to a pre-existing history of AF.
Compared to these previous reports, our study has several strengths. First, we pro-
vided a comprehensive and updated search and included more studies and a higher
number of patients, encompassing both the epidemiology of AF and the related risk of
death in patients with COVID-19; second, we focused only on those AF episodes that
developed during COVID-19, so that the relationship observed may be more clinically
relevant compared to that between history of AF and COVID-19; third, we calculated
and reported 95% PI for our estimates of AF prevalence, providing information on the
variability of the prevalence in different clinical settings [19,20]; finally, we performed an
extensive assessment of the heterogeneity observed between studies, identifying potential
moderators of the association between COVID-19 and AF.
Our findings make it possible to postulate on the pathophysiological mechanisms un-
derlying the association between AF and COVID-19. The relationship between infections,
inflammation, and the onset of AF is well known, although not completely explained [5].
Cytokine storm, oxidative stress, and atrial remodeling are among the putative phenomena
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that may trigger the onset of AF, especially in patients with an individual predisposi-
tion [5]; moreover, inflammation has been linked to complex cellular changes in atrial
myocardiocytes, which can ultimately contribute to the development of an arrhythmogenic
milieu [52]. COVID-19 has been described from inception as an inflammatory disease [53],
and targeting the dysregulated immune response was postulated as a promising thera-
peutic approach [54–58]. Indeed, the relationship between AF and COVID-19 may be—at
least partially—explained by the increased burden of systemic inflammation. For example,
higher levels of C-reactive protein and interleukin-6 were observed in COVID-19 patients
with AF, compared to patients without AF [37].
Inflammation may also trigger arrhythmias through determining a more severe clinical
course of COVID-19. Inflammatory burden during COVID-19 was associated with greater
disease severity [59] and increased risk of death [60]. On the other hand, the association
between critically ill status and the onset of AF is well established, particularly during
infections [7]; indeed, AF in our study was associated with a five-fold greater chance of
having a critical clinical state.
Taken together, these findings may be interpreted as the results of a complex interplay
between systemic inflammation, clinical status, and the onset of AF. Consistently, inflam-
mation has been indicated as one key risk factor that may trigger AF onset during critical
illness [61], and these multiple interacting mechanisms may also be involved in patients
with COVID-19.
The prevalence of AF that we found is consistent with other studies focused on non-
COVID-19 pneumonia, which reported similar or slightly higher prevalence of AF [62,63].
Although a higher prevalence of AF may have been expected in COVID-19 patients, two
remarks should be made. First, the mean age and the burden of comorbidities found in
most studies were relatively low, compared to usual general population AF cohorts, thus
indicating an overall low individual risk of AF. Second, significant heterogeneity was found
between studies, with the 95% PI pointing towards a potentially higher prevalence of AF in
further studies. Due to inconsistent reporting in the (early) original studies, only few factors
were available for our meta-regression analysis, which showed that the combination of age,
hypertension, diabetes mellitus, and geographical location may explain more than 40% of
the heterogeneity observed. Even amongst the subset of studies investigating new-onset AF,
the results indicate that the burden of risk factors may have a major role in the development
of arrhythmia. While the strict relationship between increasing age and AF is largely
known [64], as well as the association between older age and increased mortality during
COVID-19 [65], our data help underline how older age may represent a “proxy” for clinical
complexity, providing a substrate for developing conditions strongly connected with
clinical complexity and multimorbidity, such as AF [66]. Consistently, a recent systematic
review showed that increasing age, male sex, and cardiovascular comorbidities were
strong risk factors for the onset of AF in ICU patients [61]; the association between these
conditions, as well as multimorbidity, with disease severity and worse prognosis in patients
with COVID-19 has also already been highlighted [67,68]. These findings suggest that AF
may represent a “marker” of additional risk in COVID-19 patients. Indeed, patients with
AF have a 4-fold increased risk of all-cause death.
The link between AF and mortality in COVID-19 patients could be explained by
several mechanisms. Beyond the relationship with inflammation and multimorbidity, AF
may directly worsen prognosis through hemodynamic instability, thromboembolism [69],
and increased endothelial dysfunction [70]. Additionally, the results of the meta-regression
analysis, which did not identify any moderators of the risk of mortality, strengthen the idea
that AF may have a direct effect in increasing mortality in COVID-19 patients. This hypoth-
esis is also supported by our sensitivity analysis on patients with new-onset AF, which
showed a consistent 2.8-fold high risk of all-cause death, and by the disaggregated analysis
of in-hospital mortality and 30-days mortality, which gave broadly comparable results. The
phenotype of AF, including duration and recurrent episodes, may also impose different
prognosis in COVID-19 patients; however, due to insufficient data reported in the original
J. Clin. Med. 2021, 10, 2490 12 of 16
studies, we were unable to explore the contribution of specific AF characteristics on the
risk of all-cause mortality in these patients. Moreover, uncertainties exist on the risk of AF
recurrence in the long-term follow-up of patients with COVID-19. One large study found
that over one third of patients with infection-related AF presented arrhythmia recurrence
in the first year of follow-up [4], but whether this also applies to the COVID-19 scenario
needs to be identified and confirmed, as well as the potential predictors of AF recurrence.
Finally, our results leave questions open on the appropriate management of patients
who develop AF during COVID-19, particularly regarding thromboembolic risk and the
implementation of antithrombotic treatment. The role of specific therapies, including
immune modulators, antiarrhythmics, and antithrombotics on the prognosis of AF and
COVID-19 patients is still far from being elucidated, and further studies are needed to
understand whether specific strategies may have an influence on the outcome of these
subjects. Although no definitive guidance exists on the management of new-onset AF
occurring during infections, a recent large study found that these patients may experience
a high thromboembolic risk [4], suggesting that they may need to be managed similarly
to patients with non-infection related AF, also consistent with the pathophysiological hy-
potheses reported above. Moreover, the choice of antiarrhythmics for patients who develop
AF during infections is still an open debate, although some potentially relevant prognostic
differences were outlined recently [71,72]. Ultimately, the role of immunomodulating
therapies in this clinical scenario is still unclear and needs further specific investigation [73].
From a broader perspective, as AF occurring during COVID-19 may indicate increased
clinical complexity, these patients should be carefully evaluated for the presence of other
clinical conditions. The use of an integrated approach which aims, among other things, at
the optimal management of comorbidities, is currently endorsed by the recent European
AF guidelines [64], and was found to be effective in improving prognosis [74]. It is plau-
sible that a similar approach would also be beneficial in the clinical settings of patients
who experience AF during COVID-19, although further studies are needed to define the
prognosis and the optimal management of these subjects.
Limitations
Our study has several limitations. First, most studies were retrospective or not
specifically designed to estimate the prevalence of AF or its effect on outcomes. However,
this is a common limitation of many epidemiologic studies investigating the relationship
between comorbidities and COVID-19; moreover, we provided 95% PI values, which
are useful to quantify the amount of uncertainty in our estimates, and performed meta-
regressions to investigate potential sources of heterogeneity. Second, the definition of
“critical clinical disease” that we used may be prone to bias. However, the association
between AF and critical status was strong, with moderate heterogeneity between studies.
Third, a clear distinction between patients with new-onset AF and patients with both AF
and previous history of arrhythmias was available only in a subset of studies. Nonetheless,
the sensitivity analysis based on new-onset AF showed consistent results compared to
the main analysis. Fourth, according to the data availability from the original studies, we
were unable to assess the impact of other potentially relevant study-level characteristics
(including other comorbidities and previous medical conditions, smoking habit, alcohol
use, etc.) on the epidemiology of AF during COVID-19, as well as their impact on prognosis.
Finally, we were unable to explore inflammatory burden differences between AF and non-
AF patients, as well as the impact of different types and duration of AF episodes, or the
contribution of a specific treatment, on the prognosis of COVID-19 patients, since most
studies did not report laboratory parameters according to the AF status, information on
AF phenotype, or data on the prognosis according to treatment received.
5. Conclusions
In this systematic review and meta-analysis, the prevalence of AF was 8% patients
with COVID-19, and was associated with older age, male sex, hypertension, and critical
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status. Patients with AF showed a 4-fold higher risk of all-cause mortality compared to
those without AF. Similar findings were observed in patients with new-onset AF. Our
analysis underlines the detrimental role of AF in patients with COVID-19 and supports
the need for the implementation of specific and tailored strategies for the prevention,
diagnosis, and management of patients with COVID-19 and concurrent AF. Further studies
are needed to define the optimal strategies for the follow-up of these patients, particularly
regarding antithrombotic strategies.
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